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Objective: We compared mindfulness-based cognitive therapy (MBCT) with both cognitive psycholog-
ical education (CPE) and treatment as usual (TAU) in preventing relapse to major depressive disorder
(MDD) in people currently in remission following at least 3 previous episodes. Method: A randomized
controlled trial in which 274 participants were allocated in the ratio 2:2:1 to MBCT plus TAU, CPE plus
TAU, and TAU alone, and data were analyzed for the 255 (93%; MBCT  99, CPE  103, TAU  53)
retained to follow-up. MBCT was delivered in accordance with its published manual, modified to address
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suicidal cognitions; CPE was modeled on MBCT, but without training in meditation. Both treatments
were delivered through 8 weekly classes. Results: Allocated treatment had no significant effect on risk
of relapse to MDD over 12 months follow-up, hazard ratio for MBCT vs. CPE  0.88, 95% CI [0.58,
1.35]; for MBCT vs. TAU  0.69, 95% CI [0.42, 1.12]. However, severity of childhood trauma affected
relapse, hazard ratio for increase of 1 standard deviation  1.26 (95% CI [1.05, 1.50]), and significantly
interacted with allocated treatment. Among participants above median severity, the hazard ratio was 0.61,
95% CI [0.34, 1.09], for MBCT vs. CPE, and 0.43, 95% CI [0.22, 0.87], for MBCT vs. TAU. For those
below median severity, there were no such differences between treatment groups. Conclusion: MBCT
provided significant protection against relapse for participants with increased vulnerability due to history
of childhood trauma, but showed no significant advantage in comparison to an active control treatment
and usual care over the whole group of patients with recurrent depression.
Keywords: mindfulness-based cognitive therapy, major depression, relapse prevention, suicidality,
childhood trauma
Depression is a chronic relapsing condition, with relapse rates of
50%–80% and increased risk of suicide (Judd & Akiskal, 2000;
Mueller et al., 1999; Penninx et al., 2011; Solomon et al., 2000).
High risk of relapse is associated with a history of adversity and
abuse, early onset of first episode, and frequent episodes before the
index episode (Burcusa & Iacono, 2007). Previous research has
indicated that mindfulness-based cognitive therapy (MBCT) re-
duces risk of relapse by teaching relapse prevention skills to
recurrently depressed patients while in remission. It combines
psychological education from cognitive therapy for depression
with intensive practice of mindfulness meditation (Segal, Wil-
liams, & Teasdale, 2002). Six clinical trials have evaluated the
effectiveness of MBCT as prophylaxis (Bondolfi et al., 2010;
Godfrin & van Heeringen, 2010; Kuyken et al., 2008; Ma &
Teasdale, 2004; Segal et al., 2010; Teasdale et al., 2000), and a
meta-analysis revealed that, on average, MBCT reduced risk of
relapse in patients with three or more prior episodes by 43%
relative to treatment as usual (TAU; Piet & Hougaard, 2011).
Hence, the UK National Institute of Health and Clinical Excellence
(NICE) includes MBCT in its guidelines for the treatment of
recurrent depression (National Institute of Health and Clinical
Excellence, 2009).
However, evidence is lacking in two respects. First, no study has
yet compared MBCT with an active psychological treatment. This
means that we do not know to what extent the beneficial effects of
MBCT are attributable to the process of learning mindfulness
meditation skills rather than to psychological education or non-
specific factors such as group support, despite the fact that mind-
fulness meditation is widely assumed to be the component critical
to effectiveness. In order to examine these issues, we used in this
study a “dismantling” design in which cognitive psychological
education (CPE) provided a control treatment offering the same
educational process and following the same group format as
MBCT, but with no training in meditation. Outcomes for both
treatment groups were compared with TAU.
Second, evidence is converging to suggest that MBCT is effective
only for those at greater risk of relapse, with little evidence of
effectiveness for those who are less vulnerable. The two initial trials
of MBCT (Ma & Teasdale, 2004; Teasdale et al., 2000) stratified their
samples before randomization by the number of prior episodes of
major depressive disorder (MDD). Both trials revealed that, although
MBCT reduced risk of recurrence in patients with three or more prior
episodes, it increased risk of recurrence for those with only two prior
episodes (Piet & Hougaard, 2011). Furthermore, a recent Canadian
trial by Segal et al. (2010) revealed no reduction for patients in stable
remission following pharmacotherapy, assigned to either continued
antidepressant medication or MBCT, compared with placebo. How-
ever, in patients with unstable remission (Nierenberg et al., 2010),
MBCT and antidepressants reduced rate of recurrence to 28% and
27%, respectively, compared with a rate of recurrence of 71% in the
placebo group.
These studies suggest that MBCT is more effective for more
vulnerable patients: those with a greater number of prior episodes of
depression or persisting residual symptoms. However, the character-
ization of patients by number of prior episodes masks other important
differences that may be related to the efficacy of MBCT in reducing
relapse. For example, the two early trials (Ma & Teasdale, 2004;
Teasdale et al., 2000) revealed in exploratory analyses that patients
with three or more episodes had an earlier age of first onset of MDD,
and significantly more adversity in childhood and adolescence (more
abuse and more indifference from parents), whereas those with only
two prior episodes had later onset and did not differ in reported
parenting style from a “never depressed” control group. These find-
ings suggest that the differential efficacy of MBCT in people with two
versus three or more episodes of depression reflects differences be-
tween subpopulations that may differ on a range of clinical risk factors
(Ma & Teasdale, 2004). We therefore tested whether each variable
previously associated with better outcome also moderated efficacy of
MBCT in the current trial. We also stratified the sample for history of
suicidality to examine whether MBCT had differential effectiveness
in those with this risk factor. This article focuses on the main outcome
of the trial, time to relapse to major depression—the standardized
outcome reported in all previous trials of MBCT for depression and
the basis of the meta-analysis (Piet & Hougaard, 2011).
Method
Participants
We recruited participants through referrals from primary care
and mental health clinics in Oxford, England, and Bangor, North
Wales, and advertisements in the community. We assessed eligi-
bility through the Structured Clinical Interview for DSM–IV, the
Diagnostic and Statistical Manual of Mental Disorders (SCID;
First, Spitzer, Gibbon, & Williams, 2002). Inclusion criteria at
baseline assessment were (a) age between 18 and 70 years; (b)
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history of at least three episodes of major depression meeting
DSM–IV, text revision (DSM–IV–TR) criteria (American Psychi-
atric Association, 2000), of which two must have occurred within
the last 5 years, and one within the last 2 years; (c) remission for
the previous 8 weeks (with potential trial participants deemed not
to be in recovery or remission, and hence ineligible, if they
reported that at least 1 week during the previous 8 they experi-
enced either a core symptom of depression (depressed mood,
anhedonia) or suicidal feelings and at least one other symptom of
depression, which together were not attributable to bereavement,
substances, or medical condition, but were impairing functioning);
and (d) informed consent from participants and their primary care
physicians.
Exclusion criteria were (a) history of schizophrenia, schizoaf-
fective disorder, bipolar disorder, current abuse of alcohol or other
substances, organic mental disorder, pervasive developmental de-
lay, primary diagnosis of obsessive-compulsive disorder or eating
disorder, or regular nonsuicidal self-injury; (b) positive continuing
response to cognitive behavior therapy (CBT), that is, no relapse to
depression since treatment with CBT, due to the known effects of
CBT in reducing risk of relapse; (c) current psychotherapy or
counseling more than once a month; (d) regular meditation prac-
tice (meditating more than once per month); or (e) inability to
complete research assessments through difficulty with English,
visual impairment, or cognitive difficulties.
Randomization
We aimed to recruit 300 participants and randomly allocate
them between groups in the ratio 120 MBCT  TAU: 120 CPE 
TAU: 60 TAU alone. This would yield 99% power for survival
analysis with 5% significance level to detect the predicted differ-
ence of 31% in recurrence between MBCT and TAU, and 80%
power to detect the predicted difference of 18% between MBCT
and CPE (Williams et al., 2012). Reanalysis of the two original
trials of MBCT (Ma & Teasdale, 2004; Teasdale et al., 2000)
yielded negative estimates of intraclass correlation for time to
relapse (Williams, Russell, & Russell, 2008). Thus, there was no
evidence of intraclass dependency or loss of power through clus-
tering. Hence, we were able to treat participants as independent for
the purpose of power calculations. Randomization was by e-mail
to the North Wales Organisation for Randomised Trials in Health,
which used dynamic allocation (Russell, Hoare, Whitaker, Whita-
ker, & Russell, 2011) to stratify by two variables in addition to site
and recruitment cohort: antidepressant medication in last 7 days
and history of suicidality. Participants provided written consent
before assessment of eligibility and renewed that consent before
randomization. Participants were informed of the outcome of ran-
domization by letter and also by e-mail or telephone if desired.
Once they had been notified of their allocation, they were invited
to schedule a preclass interview (in the case of those allocated to
MBCT or CPE) or a TAU interview for those in the TAU arm.
Assessors derived information for stratification about past sui-
cidality from the suicidality questions of the SCID, Item 20 of the
Beck Scale for Suicidal Ideation (Beck & Steer, 1993) and the
Suicide Attempt and Self-Injury Interview (Linehan, Comtois,
Brown, Heard, & Wagner, 2006). The main variables derived from
the SCID to characterize past depression were age of onset; num-
ber of prior episodes; and occurrence of chronic depression as
defined by the DSM–IV–TR, namely, major depression that lasted
for at least 2 years. From the SCID, we also derived binary
measures of current or past anxiety disorder and of current or past
substance dependence or abuse. We asked participants to report
any antidepressant medication they had taken during the previous
week. We assessed residual depressive symptoms at trial entry by
the Hamilton Rating Scale for Depression (HAMD; Hamilton,
1960), using the 17-item version of this interviewer-rated scale.
Internal consistency for the HAMD in our study was   .73.
Additionally, participants provided self-reports on the Beck De-
pression Inventory–II (BDI-II), a well-established questionnaire
measure of depressive symptomatology that contains 21 groups of
statements, referring to the presence of symptoms over the pre-
ceding 2 weeks (Beck, Steer, & Brown, 1996). Internal consis-
tency for the BDI-II was   .90. Early adversity and abuse were
assessed using the Childhood Trauma Questionnaire (CTQ; Bern-
stein & Fink, 1997), an established self-report measure containing
28 items, validated against interview measures of childhood
trauma and maltreatment (Bernstein & Fink, 1997; Bernstein et al.,
1994). Internal consistency of a sumscore combining scores from
five subscales on emotional, physical, and sexual abuse, and emo-
tional and physical neglect showed an internal consistency of  
.94. Higher scores indicate greater severity for all three measures.
Research Governance
The Oxfordshire Research Ethics Committee C and the North
Wales Research Ethics Committee approved the trial in July 2008,
and several subsequent operational changes. Thereafter, an inde-
pendent Trial Steering Committee and Data Monitoring Subcom-
mittee oversaw the trial.
Interventions
Six cohorts received treatment between January 2009 and De-
cember 2010. We encouraged participants in all three groups to
continue current medication and attend their mental health practi-
tioners or other services as usual during the trial (TAU). We
informed participants’ general practitioners of their patients’ allo-
cated treatment, the dates of treatment sessions (if applicable), and
the point at which patients ended their participation in the trial.
MBCT. MBCT is a manualized group skills training program
(Segal et al., 2002) that integrates psychological educational as-
pects of CBT for depression with meditation components of
mindfulness-based stress reduction developed by Kabat-Zinn
(1990). It stems from experimental research showing that relapse
is more likely when, in periods of low mood, patterns of negative
thoughts and feelings associated with previous episodes of depres-
sion recur (Lau, Segal, & Williams, 2004). The program teaches
skills that enable participants to disengage from these habitual
dysfunctional cognitive routines and thus reduce the risk of relapse
into depression. In this study, MBCT comprised an individual
preclass interview followed by eight weekly 2-hr classes, including
training in meditation skills such as sustained attentional focus on
the body and breath and adopting a decentered view of thoughts as
passing mental events. The program followed the original MBCT
manual (Segal et al., 2002) except for greater emphasis on patterns
of thoughts and feelings that might be associated with suicidal
planning, factors that maintain and exacerbate such patterns, and
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preparation of explicit action plans for suicidal crises. Participants
were also invited to follow-up classes taking place 6 weeks and 6
months posttreatment, respectively. Each follow-up class lasted for
2 hr and included meditation, discussion of discoveries and diffi-
culties since the course ended, and how these were being dealt with
by participants.
CPE. The CPE program, developed for this trial, comprised
all elements of the MBCT program except the experiential culti-
vation of mindfulness through meditation practice and followed
the same format of eight weekly 2-hr classes (i.e., matched for time
with MBCT), with follow-up classes at 6 weeks and 6 months.
Thus, participants learned about the psychological processes of
relapse and were encouraged to apply what they had learned
outside the sessions, to help prevent relapse. They also learned
how to recognize the warning signs of depression and the impor-
tance of disengaging from unhelpful processes such as rumination
and experiential avoidance. CPE educated them about these pro-
cesses through interactive practical exercises and group discus-
sions. CPE participants completed all MBCT homework that in-
volved no meditation practice (pleasant and unpleasant events
calendar, automatic thoughts worksheets, relapse signature warn-
ing signs worksheets, and how to plan for times of high relapse
vulnerability—around 2 hr of homework in all). However, the
dismantling design of the study meant that we intentionally did not
match the CPE group for amount of homework with MBCT,
because CPE did not include home meditation practice, and addi-
tion of a substitute homework (often preferred in other pragmatic
designs) would have made our key scientific question unanswer-
able (see the Discussion section).
CPE participants were offered MBCT once data collection was
completed. Further details of the interventions are provided at
http://oxfordmindfulness.org/science/projects/staying-well.
Treatment engagement interview. Data from a pilot trial of
MBCT for patients with a history of suicidality in the context of a
unipolar or bipolar mood disorder (Williams et al., 2008) identified
high rates of attrition from treatment, with further analysis indi-
cating that attrition often occurred early in the treatment process
and in individuals who showed high levels of cognitive reactivity
to changes in mood and who were more prone to ruminative
brooding (Crane & Williams, 2010). In order to enhance treatment
engagement in the current trial, considerable attention was paid to
the preclass interview participants received. Therapists received a
summary of the clinical history information derived from the
baseline assessment, including details of any prior suicidal ideation
or suicidal behavior. During the interview, therapists and partici-
pants reviewed the participant’s history of depression and other
problems and jointly developed a formulation of how MBCT or
CPE would address these. Participants with high levels of brooding
were flagged, and therapists made a particular point of discussing
difficulties that might arise during treatment, at times when it
seemed that no progress was being made in dealing with negative
thoughts and feelings. Participants were welcome to contact the
therapist between sessions if they were experiencing difficulties
and therapists actively followed up participants who did not attend
treatment sessions, sending out the relevant handouts and other
materials by mail and attempting to schedule a telephone call to
cover information that had been missed.
TAU. TAU began with an interview with a trial therapist or
trained recruiter. Given that all participants were currently in
remission, there was no attempt made to specify what TAU should
be. Nevertheless, the therapist stressed the importance of the
participant seeking treatment as needed from their usual health
care provider throughout their period in the trial, and records were
kept of the treatment sought at each assessment point. These data
indicated that 21% of patients in TAU received one or more new
antidepressant prescriptions during the follow-up phase, in com-
parison to 18% of participants in MBCT and 13% of those in CPE.
Similarly, 11% of those in TAU saw a psychiatrist or community
psychiatric nurse regarding their depression at least once during
the follow-up phase in comparison to 10% of those allocated to
MBCT and 9% of those allocated to CPE. Finally, 21% of those
allocated to TAU saw a counselor, psychologist, or psychothera-
pist at least once during the follow-up phase, compared with 18%
of those allocated to MBCT and 12% of those allocated to CPE.
There were no significant differences between groups in pharma-
cological or psychiatric/psychological treatment received. All par-
ticipants were offered their treatment of choice once data collec-
tion was over, regardless of whether they were in the MBCT, CPE,
or TAU arm initially.
Therapist training and fidelity. Four therapists delivered
both MBCT and CPE, each leading six classes, and alternating
between the two therapies. All therapists were instructors in
MBCT with at least 3 years’ experience; all contributed to devel-
oping CPE and piloting it at each of the two sites. During the
trial, JMGW ensured treatment fidelity by monitoring treatment
adherence and competence for both MBCT and CPE through
weekly video conferences and the viewing of video recordings
of classes. Treatment fidelity ratings on the Mindfulness-Based
Interventions–Teaching Assessment Criteria Scale (Crane et al.,
2012, 2013; see also http://mindfulnessteachersuk.org.uk/pdf/
MBI-TACJune2012.pdf), which assesses therapist adherence to
the MBCT protocol and competence in its delivery, was 5.6 out
of 6 (with modal scores in the highest category: “Advanced”)
across the four therapists.
Treatment credibility. Participants allocated to MBCT or
CPE rated the credibility of their allocated treatment at the start of
Session 2 on three scales from 0 to 10. Though these scales slightly
favored CPE, there were no significant differences between MBCT
and CPE groups in how sensible the treatment seemed (mean
difference  0.60; 95% CI [1.25, 0.06]); confidence in treat-
ment’s capacity to prevent future depression (mean differ-
ence  0.38; 95% CI [1.00, 0.24]); or confidence in recom-
mending treatment to a friend with similar problems (mean
difference  0.40; 95% CI [1.07, 0.28]).
Assessment of Primary Outcomes
We assessed participants from September 2008 until December
2011 using fully trained assessors blind to treatment allocation—
before randomization; immediately after treatment (or at the equiv-
alent point for the TAU group); and then at 3, 6, 9, and 12 months
after treatment or equivalent. We strove to maintain blinding: For
example, we assessed participants in different buildings from those
in which treatment took place and checked assessor blindness at
the end of every assessment session. On the rare occasions on
which an assessor became unblinded due to overt disclosure by a
participant, we used an alternative assessor for all subsequent
assessments.
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The primary outcome was time until relapse to major depres-
sion, defined as meeting relevant SCID criteria for at least 2 weeks
since the previous assessment. Participants were asked to date the
onset of their episode as accurately as possible. Where they could
not give a precise date of onset, we used an algorithm to approx-
imate the date of onset for derivation of “a days to relapse”
variable.1
We recorded all SCIDs and recruited two independent psychi-
atrists to reassess a sample of 91 follow-up interviews. Psychia-
trists received only the audio-recording of the clinical interview.
Cases for independent review were selected by a researcher blind
to all participant details, who had not listened to the audio-
recordings, with the aim of including approximately two relapses
per assessor, per cohort, per assessment wave (posttreatment, 3, 6,
9, 12 months). Once each relapse interview had been identified, the
next available case within a cohort and without a relapse at the
assessment in question was selected as a control. Interrater reli-
ability between the original assessor and an independent psychia-
trist was 0.74, 95% CI [0.60, 0.87], with 87% agreement on
whether relapse had occurred.
We monitored serious adverse events (SAEs) and reported these
to the trial Data Monitoring Subcommittee and to the National
Research Ethics Service if potentially arising from a trial interven-
tion.
Statistical Analysis
Data were analyzed by treatment allocated. In the current trial,
only 7% of participants dropped out before providing any
follow-up data, and analysis of baseline characteristics revealed no
significant differences between those who dropped out before
providing follow-up data and the remainder of the sample, other
than a small difference in age. We used Cox proportional hazards
regression models (Cox, 1972; Singer & Willett, 2003), which
censored cases at relapse, or in the case of those who were
nonrelapsed and dropped out before 12 months, at the last date of
follow-up. In accordance with the agreed-upon analysis plan (Wil-
liams et al., 2010, 2012), we first tested the univariate effects of
stratification variables and potential moderators, and their interac-
tions with treatment group, on time to relapse by the Cox propor-
tional hazards regression model. We then used a forward stepwise
approach to derive a parsimonious model predicting risk of relapse
from treatment allocated and stratifying and moderator variables,
including interactions between group and other variables. This
model enabled us to examine potential interactions between pre-
dictor variables and to identify the strongest predictors among a set
of variables that was likely to be correlated. The research team
remained blind to which groups received MBCT and CPE until the
Trial Steering Committee had reviewed the primary analyses. The
funder played no role in study design or conduct, or the decision
to submit this article for publication.
Results
We enrolled and randomized 274 patients between September
2008 and October 2010 (see Figure 1). Nineteen (7%) left the trial
before any follow-up data could be collected: nine from MBCT,
seven from CPE, and three from TAU. Of these, two explicitly
withdrew from the trial, one moved away, and the remaining 16
repeatedly failed to attend scheduled follow-up appointments.
Thus, follow-up data were available for 255 participants: 99 re-
ceiving MBCT, 103 CPE, and 53 TAU. The mean time from
randomization to final follow-up did not differ significantly be-
tween groups: 467 days for MBCT; 446 days for CPE; and 462
days for TAU, F(2, 252)  1.25, p  .29.
Both treatment groups attended a median of seven of the eight
treatment sessions; 89 (90%) of MBCT participants completed
four or more sessions, compared with 97 (94%) for CPE. Partic-
ipants in MBCT completed a daily homework diary in which they
recorded whether or not they had completed a formal meditation
practice, alongside specific informal practices, which differed
from week to week. Where homework data were missing, we made
a conservative assumption that no homework had been completed.
Participants completed a formal meditation practice on an average
of 3.36 days per week (SD  1.77; range  0–6.43). There was
no significant difference in amount of practice between partici-
pants at the two study sites, with limited evidence of decline in
practice across treatment weeks (Week 1: M  3.81, SD  2.22;
Week 7: M  3.00, SD  2.60).
Participants reported 15 SAEs to the research team, five arising
from MBCT and 10 from CPE. We adjudged only one to be a
“serious adverse reaction” potentially arising from a trial treat-
ment—an episode of serious suicidal ideation following discussion
of different coping responses to low mood in CPE. The rest were
overnight admissions: 13 for physical health problems and one
following an overdose during follow-up in a patient who had
received MBCT. One participant died from an unrelated medical
condition after partially withdrawing from trial follow-up due to
illness.
Demographic and Clinical Characteristics
The 274 participants had a mean age of 43 years (SD  12
years; range  18–68) at entry to the study; 198 (72%) were
female, with 13 (5%) describing themselves as non-Caucasian.
Table 1 shows the baseline characteristics of those who provided
follow-up data by treatment group. The 19 participants lost to follow-up
were significantly younger than those who provided follow-up data, by
5.6 years (95% CI [1.5, 9.7]). There were no other significant differ-
ences between the groups.
Relapse to Major Depression
The raw relapse rates for the 255 participants (93%) with
follow-up data were 46% in the MBCT group, 50% in the CPE
group, and 53% in the TAU group. Table 2 shows the main effects
1 When the participant gave a month of onset, this was approximated to
the 15th of the month. Where the participant stated that their episode began
at the start of the month (e.g., “beginning of February”), onset was
approximated to the 1st of the month. “Early” in the month was approxi-
mated to the 8th, and “late” was approximated to the 22nd of the month.
“End” of the month was approximated to the final day of the month. Where
these algorithms derived a duration of relapse of less than 2 weeks (e.g., the
participant stated that the episode both started and ended in “January” with
no further details, leading to initial start and end dates of January 15), the
dates were expanded equally in both directions to produce a 2-week relapse
period (e.g., 8th–22nd) because the research assessor had always ensured
that the symptoms had been present for at least 2 weeks.
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of treatment group and the stratification and moderator variables,
and their interactions with treatment group. Treatment group had
no significant main effect on risk of relapse (p  .56). There were
significant univariate effects of site, residual symptoms (the
HAMD), and childhood trauma (the CTQ). Participants in the
Bangor site were more likely to relapse during the study period
(hazard ratio  1.56, 95% CI [1.10, 2.21]), as were those with
higher HAMD or childhood trauma scores. The hazard ratios for
an increase of one standard deviation at baseline were 3.54 for
HAMD (OR 1.26, 95% CI [1.07, 1.48]) and 17.79 for childhood
trauma (OR  1.28, 95% CI [1.09, 1.52]).
We used a forward stepwise approach to derive the most parsimo-
nious predictive model of time until relapse from treatment group and
all stratifying and moderator variables (see Table 3). The final model
included treatment group (not significant but essential in the presence
of interaction); site (hazard ratio now 1.43, 95% CI [0.98, 2.09]—no
longer significant, but also needed to characterize interaction); child-
hood trauma (hazard ratio for increase of 1 SD 1.26, 95% CI [1.05,
1.50]); HAMD (hazard ratio for increase of 1 SD  1.23, 95% CI
[1.03, 1.46]); a Childhood Trauma  Treatment Group interaction
(hazard ratios for increase of 1 SD  0.42, 95% CI [0.26, 0.69] for
MBCT vs. TAU; and 0.51, 95% CI [0.33, 0.79] for MBCT vs. CPE);
and a Site  Treatment Group interaction (hazard ratio  1.93, 95%
CI [0.74, 5.02], for MBCT vs. TAU; and 2.76, 95% CI [1.23, 6.21] for
MBCT vs. CPE). This Site  Treatment Group interaction, which
emerged only in stepwise modeling, resulted from a greater reduction
in risk of relapse in those allocated to MBCT in Oxford than in
Bangor.
The significant Childhood Trauma  Treatment Group interac-
tion resulted from differences between MBCT and both other trial
arms in the dependence of risk of relapse on childhood trauma
score. To characterize this interaction, we conducted further ex-
ploratory analyses, dichotomizing the sample at the median child-
hood trauma score (Mdn 39.00) into high (n 126) or low (n
129) scorers and examining the effect of treatment group on the
hazard ratio of relapse for each subsample. These analyses have
lower power than the full model of Table 3, but illustrate the effect
of the interaction in that model.
For high childhood trauma scorers, raw rates of relapse were
41%, 54%, and 65% for MBCT, CPE, and TAU, respectively. Cox
regression showed that treatment with MBCT yielded a significant
hazard ratio for subsequent relapse of 0.43 (95% CI [0.22, 0.87])
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Figure 1. Flow of participants through the study. Numbers in parentheses denote participants at Oxford, first,
and Bangor, second. MBCT  mindfulness-based cognitive therapy; CPE  cognitive psychological education;
TAU  treatment as usual.
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relative to TAU (see Figure 2a). In contrast, MBCT yielded a
nonsignificant hazard ratio of 0.61 (95% CI [0.34, 1.09]) relative
to CPE. Table 4 also shows that CPE did not differ significantly
from TAU (hazard ratio  0.72, 95% CI [0.39, 1.32]).
For low childhood trauma scorers, the rates of relapse were
51%, 45%, and 43% for MBCT, CPE, and TAU, respectively (see
Figure 2b). None of the pairwise Cox regressions were significant
in this subgroup (see Table 4).
Discussion
Principal Findings
Previous studies (Bondolfi et al., 2010; Godfrin & van Heerin-
gen, 2010; Kuyken et al., 2008; Ma & Teasdale, 2004; Segal et al.,
2010; Teasdale et al., 2000) have shown that MBCT protects
vulnerable patients from depression for at least 12 months after
treatment, yielding a preventative effect similar to that of contin-
ued antidepressant medication (Piet & Hougaard, 2011). In con-
trast, this study revealed no significant general risk reduction in
those allocated to MBCT compared with TAU or CPE.
However, analyses did show that for those with more history of
childhood trauma, MBCT made a significant difference: The haz-
ard ratio of relapse for patients receiving MBCT was 0.43 relative
to those receiving TAU alone, though in this model, the contrast
between MBCT and CPE fell short of significance (see below). For
those with less or no history of childhood trauma, MBCT did not
reduce risk of relapse compared with TAU. In the more powerful
full model, the severity of experience of childhood trauma signif-
icantly moderated both the contrasts between MBCT and CPE, and
between MBCT and TAU. This suggests that, overall, MBCT is
more effective in preventing relapse to major depression than both
CPE and TAU when severity of childhood trauma is taken into
account. However, these results should be considered in the con-
text of the strengths and limitations of the trial.
The strength of this study is that it is the largest trial of MBCT
versus TAU to date, and the first in which MBCT has been
compared with an active control treatment. Furthermore, we had
very high rates of compliance with treatment, with more than 90%
of participants allocated to both active treatments completing four
or more sessions, which previous trials adjudged an adequate
minimum dose. The trial also had low rates of dropout, with 93%
of participants providing follow-up data. We maximized external
validity by including patients who had achieved remission by
antidepressant medication, counseling, or psychotherapy other
than CBT, or no treatment at all, and included patients who were
on antidepressants at entry to the trial. This suggests that the results
reported here are generalizable to routine clinical practice. As the
vast majority (95%) of the sample was Caucasian, however, we
cannot be sure that these findings generalize to other ethnic groups.
By design, we did not balance the amount of homework between
the two active treatments. Because there is no meditation practice
in CPE, the volume of homework was less. Thus, we cannot be
sure that the superiority of MBCT over CPE and TAU in partic-
ipants reporting a history of childhood trauma was due to the
inclusion of mindfulness meditation in MBCT but not in CPE,
Table 1
Descriptive Statistics for Participants With and Without Follow-Up Data and for Those With Follow-Up Data by Allocated Treatment
Variable
Comparison between
Participants assessed at outset
Participants followed-up, by
allocated treatment
With follow-up Without follow-up MBCT CPE TAU
(n  255) (n  19) (n  99) (n  103) (n  53)
Female, n (%) 183 (72) 15 (79) 70 (71) 76 (74) 37 (70)
Age at enrolment, M (SD)a 43.82 (12.17) 38.21 (8.05) 43.99 (11.55) 43.86 (12.92) 43.43 (12.03)
Ethnicity (Caucasian), n (%) 244 (96) 17 (89) 95 (96) 97 (94) 52 (98)
Employed at enrollment, n (%) 159 (62) 13 (68) 68 (69) 57 (55) 34 (64)
Age of onset of major depression, M (SD)b 21.26 (10.93) 16.84 (6.44) 20.64 (9.62) 21.28 (11.78) 22.34 (11.61)
Number of previous episodes major depression
(5 or more), n (%) 196 (77) 16 (84) 71 (72) 85 (83) 40 (76)
Past suicidality (ideation/behavior), n (%) 203 (80) 18 (95) 80 (81) 82 (80) 41 (77)
SCID diagnosis of anxiety disorder, n (%)c,e,f 102 (40) 6 (30) 34 (35) 44 (44) 24 (45)
SCID diagnosis of alcohol/substance abuse/
dependence, n (%)d,e 36 (15) 2 (11) 17 (18) 12 (13) 7 (14)
Antidepressant use at enrollment, n (%) 114 (45) 6 (32) 44 (44) 47 (46) 23 (43)
Hamilton Rating Scale for Depression at
enrollment, M (SD) 3.20 (3.54) 3.84 (4.11) 3.17 (3.61) 3.55 (3.50) 2.57 (3.47)
Childhood Trauma Questionnaire score, M (SD) 43.81 (17.79) 44.34 (13.99) 41.78 (15.62) 46.61 (18.84) 42.15 (19.05)
Beck Depression Inventory, M (SD) 8.04 (8.11) 11.12 (10.52) 7.72 (6·68) 8.86 (9.27) 7.05 (6.94)
Note. MBCT  mindfulness-based cognitive therapy; CPE  cognitive psychological education; TAU  treatment as usual; SCID  Structured Clinical
Interview for DSM–IV.
a Participants lost to follow-up were significantly younger than those who provided follow-up data (mean difference  5.61, 95% CI [9.73, 1.49]; p 
.010). b Data available for 273 participants (missing: one allocated to MBCT). c Data available for 269 participants (missing: one lost to follow-up; two
from MBCT and two from CPE among those with follow-up). d Data available for 262 participants (missing: two from MBCT, seven from CPE, and three
from TAU, all among those with follow-up). e Percentages of those with available data. f Among those with follow-up data, four individuals met criteria
for current posttraumatic stress disorder (PTSD), six reported symptoms of PTSD in partial remission, and 24 reported a history of PTSD (in full
remission/prior history).
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rather than the requirement for regular treatment-related activity
outside sessions. The fact that the effects of CPE were intermediate
between MBCT and TAU suggests that some of the effect of
MBCT may be explained by the psychological education and
group support provided by both MBCT and CPE interventions. For
participants with a history of childhood trauma, although a signif-
icant difference emerged between MBCT and CPE as part of the
significant interaction for the whole model, loss of power when the
group was divided for exploratory analysis meant that the pairwise
comparison between MBCT and CPE fell short of significance at
this point, despite a relatively large hazard ratio of 0.61 (a reduc-
tion in hazard of 39%). To examine whether the amount of
homework in MBCT affects the outcome will require a trial that
randomly allocates patients to treatment arms with different home-
work schedules.
Two other aspects of the results deserve comment. First, we
found no main effect of antidepressant medication use at entry on
relapse. At first sight, this seems different from previous trials that
evidence that continued use of antidepressant medications prevent
relapse. However, note that these trials focus on antidepressant
medication as a treatment arm, and patients are randomly allocated
to maintenance medication as part of a design to examine their
efficacy (e.g., Segal et al., 2010). In the current trial, we stratified
for this variable only to check whether antidepressant medications
interacted with treatment allocated and did not examine antide-
pressant medication use further because such ongoing use is mul-
tidetermined, was neither controlled nor randomly assigned, and
might therefore lead to misleading results. The fact that antide-
pressant medication use at entry to the trial did not affect outcome
does not imply that antidepressant medications are ineffective,
because those who were taking antidepressant medications may
have more severe clinical status at entry to the trial and more
likelihood of returning for treatment. Second, we found evidence
of a Site  Treatment effect, due to a greater effectiveness of
MBCT in Oxford. We checked the therapist fidelity data and could
find no hint of a discrepancy in therapist competence that might
explain the site difference, nor did the sites differ in perceptions of
treatment credibility or homework compliance. We then looked for
population differences that might have accounted for it. Partici-
pants in Oxford were more likely to be single and employed and
had more years of full-time education than participants in Bangor.
However, none of these variables interacted with treatment group
to predict relapse. It remains possible that subtle but unmeasured
sociocultural differences in the two populations from which the
samples were drawn explains this effect (e.g., therapists at Bangor
reported a repeated tendency for participants in their groups to
“hear” an invitation during a meditation practice as if it was an
instruction they had to obey, and thereby to see the meditation as
a success–failure issue), and we suggest that future trials examine
such issues systematically.
Table 2
Cox Regressions for Time to Relapse: Individual Stratification and Moderator Variables and Their Interactions With
Treatment Group
Variable Hazard ratio (HR) 95% CI for HR Change in max. log likelihood df p
Group 1.17 2 .56
MBCT vs. CPE 0.83 [0.56, 1.24]
MBCT vs. TAU 0.79 [0.49, 1.27]
Stratification variables
Suicidality 1.11 [0.86, 1.43] 0.71 1 .40
Group  Suicidality 3.83 2 .15
Antidepressant use at baseline 1.17 [0.82, 1.66] 0.81 1 .37
Group  Antidepressant Use at Baseline 3.46 2 .18
Site (B) 1.55 [1.09, 2.20] 6.05 1 .01
Group  Site 5.73 2 .05
MBCT vs. CPE 2.59 [1.15, 5.81]
MBCT vs. TAU 2.07 [0.80, 5.37]
Cohort 8.33 5 .14
Group  Cohort 15.42 10 .12
Moderators
Beck Depression Inventory (BDI) 1.01 [0.99, 1.03] 1.50 1 .21
Group  BDI 2.15 2 .34
Hamilton Rating Scale for Depression (HAMD) 1.06 [1.02, 1.11] 7.29 1 .01
Group  HAMD 1.76 2 .42
Childhood Trauma Questionnaire (CTQ) 1.01 [1.00, 1.02] 7.63 1 .01
Group  CTQ 11.31 2 .00
MBCT vs. CPE 0.97 [0.94, 0.99]
MBCT vs. TAU 0.95 [0.93, 0.94]
Age of onset of major depression (Onset)a 0.99 [0.97, 1.01] 0.87 1 .35
Group  Onset 5.05 1 .08
MBCT vs. CPE 0.96 [0.92, 1.00]
MBCT vs. TAU 0.94 [0.90, 0.99]
Number of episodes of MDD (episodes) 1.01 [0.98, 1.04] 1.07 1 .30
Group  Episodes 0.78 2 .68
Note. CI  confidence interval; max.  maximum; MBCT  mindfulness-based cognitive therapy; CPE  cognitive psychological education; TAU 
treatment as usual; B  Bangor.
a Analysis of 254 participants.
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Finally we did not standardize the usual care that patients
received. All patients were encouraged to continue with existing
pharmacotherapy and seek further treatment as needed throughout
the trial. We stratified participants by use of antidepressants at
entry to the trial and excluded those who were receiving counsel-
ing or psychotherapy more than once a month at entry. Because all
patients were in remission at entry to the trial, the issue of usual
care is less critical than for an acute treatment trial. However, an
examination of care received in each group during the follow-up
phase identified no significant differences between treatment arms,
and relatively low levels of engagement in alternative treatment
across all three groups.
Although the overall absence of a difference between MBCT
and TAU in preventing relapse to depression is in contrast to the
results of the most recent meta-analysis of MBCT as prophylaxis
in major depression (Piet & Hougaard, 2011), the finding that
benefits were observed for more vulnerable participants is consis-
tent with a number of earlier studies. Indeed, earlier studies have
revealed that MBCT yielded additional benefit over TAU or pla-
cebo only for those who were vulnerable to relapse, identified
variously across studies as those with only three or more prior
episodes, those with earlier onset (Ma & Teasdale, 2004; Teasdale
et al., 2000), those with a history of abuse or adversity (Ma &
Teasdale, 2004), or those failing to achieve stable remission (Segal
et al., 2010). The findings of the present trial that the more
vulnerable patients were those with a history of childhood trauma
and that it was this group that benefited from MBCT is consistent
with these results. However, all these variables tend to be corre-
lated with one another, and we do not assume that this index of
vulnerability will necessarily always be the one that predicts better
outcome. The present sample included a greater proportion of
patients with a history of suicidal ideation or behavior than previ-
ous studies, and it is known that childhood trauma is a particularly
salient risk factor in this population. The balance of evidence to
date suggests that the variable that most strongly predicts vulner-
ability to relapse within any given clinical population may also be
the one most likely to interact with treatment condition and predict
greater benefit from prophylactic treatment.
Although the findings suggest that, when severity of childhood
trauma is taken into account, MBCT is superior to both an alter-
native psychological treatment and TAU in preventing recurrence
of depression over 12 months, there were no general differences in
Table 3
Cox Regression for Time to Relapse: Multivariate Model Examining Variables Associated With Hazard of Relapse to
Major Depression
Variablea df p Max. log likelihood Change in max. log likelihood
Block 0: Initial log likelihood 1304.26
Block 1: Group
1. Group (forced entry) 2 .56 1303.08 1.17
Block 2: Stratification variables
2. Site 1 .01 1297.04 6.05
Block 3: Modifier variables
3. CTQ 1 .01 1290.43 6.60
4. HAMD .02 1285.86 4.57
Block 4: Interactions
5. CTQ  Group 2 .00 1272.43 13.44
6. Site  Group 2 .04 1266.19 6.24
Final model 9 .01 1266.19 38.07
Components of final model Wald df p Hazard ratio (HR) 95% CI for HR
Group 2.28 2 .32
MBCT vs. CPE 0.34 1 .56 0.88 [0.57, 1.34]
(MBCT or CPE) vs. TAU 1.98 1 .16 0.73 [0.47, 1.13]
MBCT vs. TAUb 2.26 (1) .13 0.68 [0.42, 1.12]
Site 3.43 1 .06 1.43 [0.97, 2.09]
CTQ 6.42 1 .01 1.01 [1.00, 1.02]
HAMD 5.31 1 .02 1.06 [1.00, 1.11]
CTQ  Group 13.56 2 .00
CTQ  (MBCT vs. CPE) 9.02 1 .00 0.96 [0.94, 0.98]
CTQ  (MBCT or CPE) vs. TAU 7.24 1 .00 0.97 [0.95, 0.99]
CTQ  (MBCT vs. TAU)b 12.46 (1) .01 0.95 [0.92, 0.97]
Site (B)  Group 6.12 2 .04
Site  (MBCT vs. CPE) 6.06 1 .01 2.76 [1.23, 6.21]
Site  (MBCT or CPE) vs. TAU 0.11 1 .74 1.15 [0.49, 2.71]
Site  (MBCT vs. TAU)b 1.79 (1) .18 1.92 [0.73, 5.01]
Note. Max.  Maximum; CTQ  Childhood Trauma Questionnaire; HAMD  Hamilton Rating Scale for Depression; CI  confidence interval;
MBCT  mindfulness-based cognitive therapy; CPE  cognitive psychological education; TAU  treatment as usual; B  Bangor.
a Analysis of 255 participants with follow-up data. Other variables considered during the stepwise process but not included in the final model were gender;
stratifying variables at baseline, namely, cohort, suicidality, and current antidepressant use; and moderators at baseline, namely, episodes of major
depression, Beck Depression Inventory, Beck Hopelessness Scale, and Beck Scale for Suicide Ideation. b As the two contrasts of interest (MBCT vs. CPE
and MBCT vs. TAU) are not orthogonal, we derived these rows by rerunning the model with group contrasts MBCT vs. TAU and (MBCT or TAU) vs.
CPE (not shown).
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outcome according to treatment allocated in the present trial. The
crude rate of relapse in the TAU arm of the present trial, at 53%,
was low compared with earlier studies that also looked at patients
with three or more prior episodes (e.g., 66% in the first trial of
MBCT, Teasdale et al., 2000, and 78% in its replication, Ma &
Teasdale, 2004). This improved outcome for people receiving
usual care in the present trial may reflect improved management of
patients with major depression in the 13 years since the first trial
of MBCT. It is also possible that given NICE guidelines in the UK
health system, TAU may contain more empirically supported
interventions than previous research or current practice in other
studies. This potentially makes even the TAU control very strong,
and might be contributing to the lack of findings.
Additionally, because our participants had a higher frequency of
prior suicidality than has been typical in previous trials, the pri-
mary care physicians may have been more vigilant in the TAU
condition, which may partially explain the lack of a main effect of
treatment on outcome, similar to that suggested by the authors of
one previous trial of MBCT (Bondolfi et al., 2010).
The overall pattern of data from this and previous trials in which
the more vulnerable patients appear to do well with MBCT is
different from that observed with psychological treatments for
acute depression, such as cognitive therapy. For acute treatments,
those with better premorbid history show a better response to
treatment, whereas those with early age of onset, greater number of
prior episodes, and a history of trauma tend to do less well
(Harkness, Bagby, & Kennedy, 2012; Nanni, Uher, & Danese,
2012). It is possible that this may not be a difference between
MBCT and these acute treatments themselves. Instead, the relevant
difference may be between any psychosocial approach when used
for acute treatment and when used prophylactically. For example,
two studies using cognitive therapy as prophylaxis revealed better
outcomes for those who were more vulnerable (Bockting et al.,
2005; Jarrett et al., 2001). We suggest that prophylactic treatment
may have greater benefits for more vulnerable patients in remis-
sion because, despite the absence of acute symptoms, their habitual
dysfunctional thought patterns react to slight changes in mood, and
can thus become the focus of the treatment (Hollon, Thase, &
Markowitz, 2002; Lau et al., 2004; Williams, Barnhofer, Crane, &
Beck, 2005). Once in remission, those who are less vulnerable may
have limited access to mood-related reactivation of dysfunctional
content, so neither cognitive therapy nor MBCT adds therapeutic
effect. However, it remains true that MBCT may have been par-
ticularly beneficial for those with a history of childhood trauma
because certain elements of the approach (e.g., acceptance, self-
compassion, and decentering) are well matched for addressing the
factors that increase risk in these patients, particularly in the
adapted form used in the present trial. Indeed, MBCT may facil-
Figure 2. Proportions of patients who survived without relapse during follow-up in those with high (a: n 
126) and low (b: n  129) Childhood Trauma Questionnaire (CTQ) scores. MBCT  mindfulness-based
cognitive therapy plus TAU; CPE  cognitive psychological education plus TAU; TAU  treatment as usual.
Table 4
Relapse by Treatment Group by Childhood Trauma
Questionnaire (CTQ) Scores
Variable Hazard ratio CI p
Low CTQ scoresa
MBCT vs. CPE 1.17 [0.66, 2.08] .59
MBCT vs. TAU 1.30 [0.67, 2.51] .44
CPE vs. TAU 1.13 [0.56, 2.26] .74
High CTQ scoresb
MBCT vs. CPE 0.61 [0.34, 1.09] .09
MBCT vs. TAU 0.43 [0.22, 0.87] .01
CPE vs. TAU 0.72 [0.39, 1.32] .29
Note. CI  confidence interval; MBCT  mindfulness-based cognitive
therapy; CPE  cognitive psychological education; TAU  treatment as
usual.
a Low CTQ scores: MBCT n  55, CPE n  44, TAU n  30. b High
CTQ scores: MBCT n  44, CPE n  59, TAU n  23.
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itate emotional processing by encouraging participants to remain
in contact with painful material rather than avoiding it or becoming
entangled in rumination about it. However, further research, com-
paring CT and MBCT as prophylactic treatments, would be nec-
essary to test these specific hypotheses.
In short, our findings add to the growing body of evidence that
psychological interventions, delivered during remission, may have
particular beneficial effects in preventing future episodes of major
depression, but may be especially relevant for those at highest risk
of relapse. The pattern of data that emerges from all existing trials
suggests that future research should now give particular attention
to characterizing indices of vulnerability so that the particular
treatment characteristics that might address them can be clearly
identified.
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